期刊文献+

肠道病毒71型疫苗的中和抗体应答研究 被引量:5

The study of neutralizing antibody responses induced by new entrovirus 71 vaccines
原文传递
导出
摘要 目的:比较我国不同企业研发的肠道病毒71型(EV71)疫苗原液和成品疫苗的小鼠中和抗体应答,为疫苗临床试验提供依据。方法:应用来源于3家疫苗研发企业的EV71疫苗原液(Y1、Y2、Y3),以及相应原液制备的3批成品疫苗(临床申报剂量:M1、M2、M3;相同抗原含量:M1-1、M2-1、M3-1),分别采取2针程序免疫小鼠,检测免疫1针和2针后血清中和抗体效价。结果:分别来自不同生产企业的3个EV71疫苗原液免疫原性相近,免疫剂量均为430 U/0.5 mL/只时,1针后中和抗体阳性率为83.3%~90.0%,2针均为100%,中和抗体效价分别为1∶34.9~1∶45.9和1∶139.4~1∶285.7;与Al(OH)3吸附后,3批成品疫苗的免疫原性均出现明显增强,162 U/0.5 mL/只的剂量即均可得到与430 U/0.5 mL/只原液相近的抗体阳转率和效价,2针免疫后M3-1抗体效价显著高于M1-1和M2-1(1∶357.3、1∶111.3和1∶97.9,P分别为0.004和0.001)。当3批疫苗均采用临床申报剂量免疫时(162,493,506 U/0.5 mL/只),1针免疫后中和抗体阳性率(80%~100%)和抗体效价(1∶46.8~1∶115.4)均无显著性差异(P值均>0.05),2针后中和抗体阳性率均为100%,M3批抗体效价显著高于M1批(1∶958.2、1∶316.8,P值为0.017)。结论:3家企业EV71原液的免疫原性接近,成品疫苗2针免疫后均可诱导高效价中和抗体产生,但不同企业的中和抗体升高水平呈现差别,提示临床试验中需重点比较含佐剂疫苗加免后的免疫原性。 Objective: To compare the neutralizing antibody(NTAb) responses of vaccine stock solutions and final vaccines of Enterovirus 71(EV71) in mice,and provide bases for the further clinical trails of EV71 vaccines.Methods: The immunization schedule consisted of two inoculations in mice separately.ICR mice were immunized with three kinds of aqueous bulks of EV71(Y1,Y2,Y3) from three enterprises and three kinds of EV71 finial lot vaccines(Clinical declaring dose: M1,M2,M3;Equal antigenic concentration: M1-1,M2-1,M3-1).And the NTAb titers of sera were tested after the first inoculation and the second inoculation,respectively.Results: Three kinds of aqueous bulks from different strains and preparations showed the close immunogenicity.When immunizing dose was 430 U /0.5 mL / each mouse,the positive rate of NTAb was 83.3%-90.0% after the 1st inoculation and 100% after the 2ndinoculation;with Geometric Mean Titers(GMTs) of NTAb was 1∶ 34.9-1∶ 45.9 and 1∶ 139.4 1∶ 285.7,respectively.Moreover,the immunogenicity of three bulk finished vaccines after adsorbed with Al(OH) 3 all significantly increased,in result the positive rate of NTAb of finished vaccines(162 U /0.5 mL / each mouse) was close to that of vaccine stock solutions(430 U /0.5 mL / each mouse).After two immunizations,GMTs of M3 1 was significantly higher than that of M1-1 and M2-1(1 ∶ 357.3,1 ∶ 111.3,1 ∶ 97.9;P = 0.004 and 0.001).When clinical declaring doses(162,493,506 U /0.5 mL / each mouse) were employed for three vaccine products,there existed no significant difference between the positive rates of NTAb(80%-100%) and between antibody GMTs(1∶ 46.8-1∶ 115.4) after the 1st inoculation(P 0.05),and the positive rates of NTAb were all 100% after the 2nd inoculation.In addition,antibody GMTs of M3 was significantly higher than that of M1(1∶ 958.2,1∶ 316.8;P = 0.017).Conclusion: The immunogenicity of EV71 vaccine aqueous bulk solutions from three different enterprises are close to each other and high-titers NTAb is induced after two inoculations.However,significant difference in increased levels of NTAb among finial lot vaccines from different enterprises is observed,which suggests that the comparison of immunogenicity should be focused on vaccines containing aluminium adjuvant in clinical trails after boost dose.
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第8期1280-1284,共5页 Chinese Journal of Pharmaceutical Analysis
关键词 手足口病(HFMD) 肠道病毒71型(EV71) 中和抗体 免疫原性 疫苗 Hand foot and mouth disease(HFMD) Enterovirus 71(EV71) neutralizing antibody(NTAb) immunogenicity vaccine
  • 相关文献

参考文献1

二级参考文献13

  • 1董晓楠,应剑,陈应华.1970~2004年全球肠道病毒71型分离株的分子流行病学分析[J].科学通报,2007,52(9):1021-1027. 被引量:108
  • 2Schmidt NJ,Lennette EH,Ho HH.An apparently new enterovirus isolated from patients with disease of the central nervous system.J Infect Dis,1974,129(3):304-309.
  • 3Herrero LJ,Lee CS,Hurrelbrink RJ,et al.Molecular epidemiology of enterovirus 71 in penisular Malaysia,1997 -2000.Arch Virol,2003,148(7):1369-1385.
  • 4Wang JR,Tuan YC,Tsai liP,et al.Change of major genotype of entcrovirus 71 in outbreaks of hand-foot-and-mouth disease in Taiwan between 1998 and 2000.J Clin Microbiol,2002,40 (1):10-15.
  • 5Scotto-Lavino E,Du G,Frohman MA.3' end eDNA amplification using classic RACE.Nat Pro'toe,2006,1 (6):2742-2745.
  • 6Scotto-Lavino E,Du G,Frohman MA.5' end cDNAamplification using classic RACE.Nat Protoc,2006,1 (6):2555-2562.
  • 7Brown BA,Oberste MS,Alexander JP Jr,et al.Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998.J Virol,1999,73(12):9969-9975.
  • 8Yoke-Fun C,AbuBakar S.Phylogenetie evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes.BMC Microbiol,2006,6:74.
  • 9Lin KR,Hwang KP,Ke GM,et al.Evolution of EV71 genogroup in Taiwan from 1998 to 2005:an emerging of subgenogroup C4 of EV71.J Med Virol,2006,78(2):254-262.
  • 10Cardosa M J,Perera D,Brown BA,et al.Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region:comparative analysis of the VP1 and VP4 genes.Emerg Infect Dis,2003,9(4):461-468.

共引文献15

同被引文献55

  • 1朱振久,张冉,杨惠军,王庆林,钟志宏,李启星.短程免疫法制备高效价抗血清研究[J].湖南师范大学学报(医学版),2006,3(1):42-44. 被引量:13
  • 2谢忠平,宋霞,李文忠,熊秋霞,李华,崔萍芳,全文琦,丁雪凤.氯仿抽提细胞培养物中纯化甲肝病毒[J].中国公共卫生,2004,20(3):298-299. 被引量:5
  • 3赵香汝,徐彤,靳喜鹏,崔红玉.接种不同剂量的新城疫疫苗对鸡免疫应答的影响[J].中国兽医杂志,2005,41(7):17-17. 被引量:9
  • 4覃艳春,陆金兰,陆吉利,韦启后.免疫血清制备方法改良初探[J].右江民族医学院学报,2005,27(6):892-892. 被引量:11
  • 5陈燕飞.抗原与免疫血清的制备[J].长治学院学报,2006,23(2):17-19. 被引量:10
  • 6Chen KT, Chang HL, Wang ST, et al. Epidemiologic features of hand-foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-2005 [ J]. Pediatrics, 2007, 120 (2) : e244- e252.
  • 7Wang CY, Li LF, Wu MH, et al. Fatal coxsackievirus A16 infec- tion[ J]. Pediatr Infect Dis J ,2004, 23 ( 3 ) :275-276.
  • 8Iwai M, Masaki A, Hasegawa S, et al. Genetic changes of cox- sackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007 [J]. Jpn J Infect Dis, 2009, 62(4) :254-259.
  • 9Sehmidt NJ, Lennette EH, Ho HH. An apparently new enterovir- us isolated from patients with disease of the central nervous system[J]. J Infect Dis, 1974, 129(3) :304-309.
  • 10Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiolo- gy, pathogenesis and control of enterovirus 71 [ J ]. Lancet Infect Dis, 2010, 10(11) :778-790.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部